Business Description
St Pharm Co Ltd
ISIN : KR7237690003
Compare
Compare
Traded in other countries / regions
237690.Korea IPO Date
2016-06-23Description
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm's business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical's business and development of oligonucleotide therapeutics. The company's products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.69 | |||||
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | 3.39 | |||||
| Interest Coverage | 7.9 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.04 | |||||
| Beneish M-Score | -2.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 31.6 | |||||
| 3-Year FCF Growth Rate | -2.9 | |||||
| 3-Year Book Growth Rate | 8.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 37.67 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.26 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.82 | |||||
| 9-Day RSI | 42.95 | |||||
| 14-Day RSI | 47.54 | |||||
| 6-1 Month Momentum % | 20.18 | |||||
| 12-1 Month Momentum % | 11.51 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | |||||
| Quick Ratio | 2.22 | |||||
| Cash Ratio | 1.45 | |||||
| Days Inventory | 290.95 | |||||
| Days Sales Outstanding | 91.43 | |||||
| Days Payable | 27.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.52 | |||||
| Dividend Payout Ratio | 0.43 | |||||
| Forward Dividend Yield % | 0.52 | |||||
| 5-Year Yield-on-Cost % | 0.52 | |||||
| 3-Year Average Share Buyback Ratio | -0.3 | |||||
| Shareholder Yield % | -1.99 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 36.3 | |||||
| Operating Margin % | 9.9 | |||||
| Net Margin % | 7.95 | |||||
| FCF Margin % | -8.52 | |||||
| ROE % | 5.67 | |||||
| ROA % | 3.37 | |||||
| ROIC % | 3.72 | |||||
| 3-Year ROIIC % | 15.82 | |||||
| ROC (Joel Greenblatt) % | 5 | |||||
| ROCE % | 4.34 | |||||
| Years of Profitability over Past 10-Year | 7 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 83.95 | |||||
| Forward PE Ratio | 37.67 | |||||
| PE Ratio without NRI | 83.95 | |||||
| Shiller PE Ratio | 96.03 | |||||
| PS Ratio | 6.69 | |||||
| PB Ratio | 4.41 | |||||
| Price-to-Tangible-Book | 4.65 | |||||
| Price-to-Operating-Cash-Flow | 81.58 | |||||
| EV-to-EBIT | 84.19 | |||||
| EV-to-EBITDA | 41.06 | |||||
| EV-to-Revenue | 7.08 | |||||
| EV-to-FCF | -83.18 | |||||
| Price-to-Graham-Number | 4.21 | |||||
| Price-to-Net-Current-Asset-Value | 22.61 | |||||
| Earnings Yield (Greenblatt) % | 1.19 | |||||
| FCF Yield % | -1.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
St Pharm Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 272,887.299 | ||
| EPS (TTM) (â‚©) | 1153 | ||
| Beta | 0.36 | ||
| Volatility % | 53.14 | ||
| 14-Day RSI | 47.54 | ||
| 14-Day ATR (â‚©) | 6641.671566 | ||
| 20-Day SMA (â‚©) | 104900 | ||
| 12-1 Month Momentum % | 11.51 | ||
| 52-Week Range (â‚©) | 59900 - 120800 | ||
| Shares Outstanding (Mil) | 19.46 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
St Pharm Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
St Pharm Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
St Pharm Co Ltd Frequently Asked Questions
What is St Pharm Co Ltd(XKRX:237690)'s stock price today?
The current price of XKRX:237690 is â‚©98900.00. The 52 week high of XKRX:237690 is â‚©120800.00 and 52 week low is â‚©59900.00.
When is next earnings date of St Pharm Co Ltd(XKRX:237690)?
The next earnings date of St Pharm Co Ltd(XKRX:237690) is .
Does St Pharm Co Ltd(XKRX:237690) pay dividends? If so, how much?
The Dividend Yield %  of St Pharm Co Ltd(XKRX:237690) is 0.52% (As of Today), Highest Dividend Payout Ratio of St Pharm Co Ltd(XKRX:237690) was 1.57. The lowest was 0.14. And the median was 0.37. The  Forward Dividend Yield % of St Pharm Co Ltd(XKRX:237690) is 0.52%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers